Wasson J C, Saylors R L, Zeltzer P, Friedman H S, Bigner S H, Burger P C, Bigner D D, Look A T, Douglass E C, Brodeur G M
Department of Pediatrics, Washington University School of Medicine, St. Louis, Missouri 63110.
Cancer Res. 1990 May 15;50(10):2987-90.
Despite a considerable amount of information concerning chromosomal and molecular abnormalities found in gliomas in adults, relatively little is known regarding these abnormalities in pediatric brain tumors. We have analyzed DNA from 37 primary brain tumors and 4 tumor-derived cell lines for oncogene amplification. Probes utilized represent 11 known oncogenes (erbB1, gli, neu, myc, L-myc, N-myc, H-ras, K-ras, N-ras, sis, and src). Of 20 primary medulloblastomas studied, only one tumor was found to have erbB1 amplification. In contrast, of the 4 medulloblastoma cell lines studied, 1 had c-myc amplification, 1 had erbB1 amplification, and 1 had amplification of N-myc. Twelve glial brain tumors were analyzed, and only 1 case with amplification of the erbB1 oncogene was found. Other tumors studied include 1 meningioma, 2 ependymomas, 1 anaplastic ependymoma, and 1 cerebral primitive neuroectodermal tumor, none of which had oncogene amplification. These results suggest that oncogene amplification is relatively uncommon in primary medulloblastomas, but the frequency and diversity of oncogene amplification is greater in tumors that can be established as cell lines. The lower frequency of erbB1 amplification in glial brain tumors in children compared to adults is consistent with the generally lower grade of glial tumor histology seen in pediatric patients. However, the case with amplification of the erbB1 oncogene represented 1 of 2 cases of glioblastoma multiforme we studied, which suggests that pediatric glioblastoma multiforme may have a similar frequency of erbB1 oncogene amplification to glioblastomas seen in adults. Our results suggest that oncogene amplification is a relatively uncommon mechanism of oncogene activation in pediatric brain tumors, and they provide molecular evidence for heterogeneity in tumors classified as medulloblastomas.
尽管已掌握了大量有关成人胶质瘤中染色体和分子异常的信息,但对于儿童脑肿瘤中的这些异常却知之甚少。我们分析了37例原发性脑肿瘤和4种肿瘤衍生细胞系的DNA,以检测癌基因扩增情况。所使用的探针代表11种已知癌基因(erbB1、gli、neu、myc、L-myc、N-myc、H-ras、K-ras、N-ras、sis和src)。在研究的20例原发性髓母细胞瘤中,仅发现1例肿瘤存在erbB1扩增。相比之下,在研究的4种髓母细胞瘤细胞系中,1种有c-myc扩增,1种有erbB1扩增,1种有N-myc扩增。分析了12例胶质脑肿瘤,仅发现1例存在erbB1癌基因扩增。研究的其他肿瘤包括1例脑膜瘤、2例室管膜瘤、1例间变性室管膜瘤和1例脑原始神经外胚层肿瘤,均未发现癌基因扩增。这些结果表明,癌基因扩增在原发性髓母细胞瘤中相对不常见,但在可建立细胞系的肿瘤中,癌基因扩增的频率和多样性更高。与成人相比,儿童胶质脑肿瘤中erbB1扩增频率较低,这与儿科患者中胶质肿瘤组织学分级普遍较低相一致。然而,erbB1癌基因扩增的病例是我们研究的2例多形性胶质母细胞瘤中的1例,这表明儿童多形性胶质母细胞瘤的erbB1癌基因扩增频率可能与成人多形性胶质母细胞瘤相似。我们的结果表明,癌基因扩增是儿童脑肿瘤中癌基因激活的一种相对不常见的机制,并且为归类为髓母细胞瘤的肿瘤异质性提供了分子证据。